Business Wire

CA-FORESCOUT-TECHNOLOGIE

13.1.2024 15:53:28 CET | Business Wire | Pressemeddelelse

Del
Sandworm har ikke alene skylden: Forescout Research afdækker nye beviser for cyberangreb på energisektoren i Danmark

Forescout, en global leder inden for cybersikkerhed løftede i dag sløret for "Clearing the Fog of War", en rapport, der præsenterer nye beviser for to tidligere dokumenterede angreb, der ramte den danske energisektor i maj 2023.

Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20240110894177/da/

For at se dette indhold fra mms.businesswire.com, så skal du give din accept på toppen af denne side.

Clearing the Fog of War (Source: Forescout)

Forescout Research – Vedere Labs gennemførte en uafhængig analyse af disse angreb og afslørede en større kampagne, der ikke fuldt ud kunne tilskrives Advanced Persistent Threat-gruppen Sandworm, sammen med andre fund, som det danske cybersikkerhedscenter SektorCERT ikke offentliggjorde i sin rapport fra november 2023.

I sine observationer af Adversary Engagement Environment (AEE) identificerede Vedere Labs to vigtige resultater:

  • Sandworm er ikke den fælles trusselsaktør: Forescout-forskerne påviste en anden teknik til at ramme den kritiske infrastruktur i den efterfølgende bølge end den, der blev brugt i første angrebsbølge. Dette tyder på, at Sandworm ikke kan udpeges som den APT-gruppe, der er forbundet med begge angrebsbølger.
  • Masseudnyttelse blev videreført af en copycat: Den anden bølge af angreb udnyttede upatchede firewalls ved hjælp af en ny "populær" CVE-2023-27881 og yderligere IP-adresser, der ikke blev rapporteret i SektorCERT-rapporten. Meget tyder på, at den anden bølge var en del af en separat masseudnyttelseskampagne.

"At skelne mellem en statsstøttet kampagne, der har til formål at forstyrre kritisk infrastruktur, og en kriminel bølge af masseudnyttelseskampagner, samtidig med at man tager højde for potentielle overlap mellem de to, er nemmere set i bakspejlet end i øjeblikkets hede," bemærker Elisa Costante, VP of Research hos Forescout Research – Vedere Labs. "Denne rapport understreger betydningen af at kontekstualisere observerede hændelser med omfattende trussels- og sårbarhedsefterretninger med henblik på at forbedre OT-netværksovervågning og udvikle bedre hændelsesresponsplaner."

Læs bloggen: Clearing the Fog of War – En kritisk analyse af de seneste cyberangreb på energisektoren i Danmark og Ukraine

Efter den anden hændelse blev yderligere angreb i de efterfølgende måneder rettet mod udsatte enheder i kritiske infrastrukturer verden over. Forescout-forskere registrerede adskillige IP-adresser, der forsøgte at udnytte Zyxel-sårbarheden CVE-2023-28771, så sent som i oktober 2023, på tværs af forskellige enheder, herunder yderligere Zyxel-firewalls. I øjeblikket bruger seks forskellige elselskaber i europæiske lande Zyxel-firewalls, og de kan således fortsat være følsomme over for potentiel udnyttelse af ondsindede aktører.

Denne nyere dokumentation understreger nødvendigheden af, at energivirksomheder og organisationer, der fører tilsyn med kritisk infrastruktur, er opmærksomme på aktuelle trusselsefterretninger, herunder oplysninger om ondsindede IP'er og kendte udnyttede sårbarheder. Regeringer tager i stigende grad proaktive forholdsregler ved at afsætte midler til initiativer, der har til formål at styrke sikkerheden for kritisk infrastruktur inden for energisektoren. Navnlig har det amerikanske energiministerium annonceret et nyt finansieringsinitiativ og øremærket 70 millioner dollars til dette formål så sent som i sidste uge.

Forescout Research gennemførte denne analyse ved hjælp af deres AEE, som omfatter både virkelige og simulerede forbundne enheder. Dette miljø fungerer som et dybdegående værktøj til at lokalisere hændelser og skelne mellem trusselsaktørers mønstre på et højt detaljeret niveau. Målet er at forbedre reaktionerne på komplicerede angreb på kritisk infrastruktur ved hjælp af den dybere indsigt og forståelse, der opnås fra dette specialiserede testmiljø.

Flere oplysninger kan findes i den fulde rapport, "Clearing the Fog of War".

Om Forescout

Forescout Technologies, Inc. er en global leder inden for cybersikkerhed, der løbende identificerer, beskytter og hjælper med at sikre overholdelse af alle administrerede og ikke-administrerede forbundne cyberaktiver – IT, IoT, IoMT og OT. Gennem mere end 20 år har Fortune 100-organisationer og offentlige myndigheder betroet Forescout at stille leverandøruafhængig, automatiseret cybersikkerhed til rådighed i stor skala. Forescout®-platformen leverer omfattende løsninger inden for netværkssikkerhed, risiko- og eksponeringsstyring samt udvidet detektion og respons. Med gnidningsfri kontekstdeling og workflow-orkestrering via økosystempartnere giver det kunderne mulighed for mere effektivt at håndtere cyberrisici og afværge trusler.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.

Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20240110894177/da/

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye